Hung C Tran
Overview
Explore the profile of Hung C Tran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shackleford G, Mahdi M, Moats R, Hawes D, Tran H, Finlay J, et al.
PLoS One
. 2019 Jan;
14(1):e0206394.
PMID: 30608927
Leptomeningeal metastasis remains a difficult clinical challenge. Some success has been achieved by direct administration of therapeutics into the cerebrospinal fluid (CSF) circumventing limitations imposed by the blood brain barrier....
2.
Marachelian A, Villablanca J, Liu C, Liu B, Goodarzian F, Lai H, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5374-5383.
PMID: 28559462
We determined whether quantifying neuroblastoma-associated mRNAs (NB-mRNAs) in bone marrow and blood improves assessment of disease and prediction of disease progression in patients with relapsed/refractory neuroblastoma. mRNA for CHGA, DCX,...
3.
Tran H, Wan Z, Sheard M, Sun J, Jackson J, Malvar J, et al.
Clin Cancer Res
. 2016 Nov;
23(3):804-813.
PMID: 27756784
Purpose: Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC). Galunisertib, an inhibitor of TGFβR1, was examined for its ability to enhance the efficacy of...
4.
Jackson J, Tran H, Stein J, Shimada H, Patel A, Marachelian A, et al.
J Surg Res
. 2016 Jul;
204(1):109-13.
PMID: 27451875
Background: Although patients with peripheral neuroblastoma (NB; pelvic and thoracic) typically have better outcomes and less aggressive disease compared with patients with abdominal disease, little has been published with regard...
5.
Tran H, Marachelian A, Venkatramani R, Jubran R, Mascarenhas L
Pediatr Hematol Oncol
. 2015 Jan;
32(1):26-31.
PMID: 25551355
Patients with relapsed or refractory neuroblastoma have poor long-term survival. New therapeutic regimens are needed. Doxorubicin and cisplatin are commonly used in the treatment of high-risk neuroblastoma. Oxaliplatin, a platinum...
6.
Xu Y, Sun J, Sheard M, Tran H, Wan Z, Liu W, et al.
Cancer Immunol Immunother
. 2013 Aug;
62(10):1637-48.
PMID: 23982484
Background: Treatment for children with high-risk neuroblastoma with anti-disialoganglioside mAb ch14.18, IL-2, and GM-CSF plus 13-cis-retinoic acid after myeloablative chemotherapy improves survival, but 40 % of patients still relapse during...
7.
Tran H, Gardner S, Weiner H, Liebes L, Finlay J
J Oncol Pharm Pract
. 2013 Aug;
20(3):229-32.
PMID: 23929729
Objective: To determine the feasibility and toxicity profile of topotecan administered as a seven-day continuous intrathecal infusion for patients with leptomeningeal metastasis secondary to recurrent or progressive central nervous system...